Details for Patent: 10,383,834

Which drugs does patent 10,383,834 protect, and when does it expire?

Patent 10,383,834 protects OFIRMEV and is included in one NDA.

This patent has four patent family members in three countries.

Summary for Patent: 10,383,834

Title:	Reduced dose intravenous acetaminophen
Abstract:	Described herein are compositions and methods for intravenous administration of acetaminophen at a single dose level of less than about 1000 mg for the treatment or prevention of pain (e.g., postoperative pain) and/or fever.
Inventor(s):	Royal; Mike Allan (San Diego, CA), Breitmeyer; James Bradley (Rancho Santa Fe, CA)
Assignee:	Mallinckrodt Hospital Products IP Limited (Dublin, IE)
Application Number:	15/979,154
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,383,834
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 10,383,834

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mallinckrodt Hosp	OFIRMEV	acetaminophen	SOLUTION;INTRAVENOUS	022450-001	Nov 2, 2010		DISCN	Yes	No						MODIFIED DOSING REGIMEN FOR THE REDUCTION OF FEVER
Mallinckrodt Hosp	OFIRMEV	acetaminophen	SOLUTION;INTRAVENOUS	022450-001	Nov 2, 2010		DISCN	Yes	No						MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MILD TO MODERATE PAIN

International Family Members for US Patent 10,383,834

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2705733
Japan	2011503198
Japan	5909750
World Intellectual Property Organization (WIPO)	2009064928